Lymphoma; FDG; Positron emission tomography; Staging; Response to treatment; Lymphome; Tomographie par émission de postions; Bilan d'extension; Réponse aux traitements
Abstract :
[en] Abstract Mounting evidence supports the major role of [18F]FDG PET-CT in the assessment of response to chemotherapy in lymphoma. The five-point scale to grade response is becoming widely used both in practice and response-adapted trials. In 2014, a malignant lymphomas imaging working group composed of representatives from major international cooperative groups published revised guidelines concerning the role of imaging in the staging and response assessment of lymphoma. This paper summarizes the main recommendations to facilitate their clinical routine applications.
Disciplines :
Radiology, nuclear medicine & imaging Oncology
Author, co-author :
Barrington, S. F.; St Thomas' Hospital - LONDON - UK > PET Imaging Centre
Fosse, P.; UNIVERSITY OF ANGERS - FRANCE > DEPARTMENT OF NUCLEAR MEDICINE
WITHOFS, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de médecine nucléaire et imagerie onco
Itti, E.; Centre Hospitalier Universitaire Henri Mondor - CRETEUIL - FRANCE > DEPARTMENT OF NUCLEAR MEDICINE
Hustinx, Roland ; Université de Liège > Département des sciences cliniques > Médecine nucléaire
Couturier, Olivier-François; UNIVERSITY OF ANGERS - ANGERS - FRANCE > DEPARTMENT OF NUCLEAR MEDICINE
Meignan, M.; Centre Hospitalier Universitaire Henri Mondor - CRETEUIL - FRANCE > DEPARTMENT OF NUCLEAR MEDICINE
Language :
English
Title :
Recommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT
Alternative titles :
[fr] Recommandations pour évaluer l'extension et la réponse à la thérapie des lymphomes avec la TEP/TDM au [18F]FDG
Publication date :
2016
Journal title :
Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique
Cheson B.D. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011, 29:1844-1854.
Colombat P., Lissandre S., Foussard C. Lymphomes malins non hodgkiniens à petites cellules : facteurs pronostiques et traitements. Medecine Nucleaire 2009, 33:473-475.
Solal-Céligny P., Roy P., Colombat P., White J., Armitage J.O., Arranz-Saez R., et al. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
Hoster E., Dreyling M., Klapper W., Gisselbrecht C., van Hoof A., Kluin-Nelemans H.C., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994. The International Non-Hodgkin"s Lymphoma Prognostic Factors Project.
Juweid M.E., Stroobants S., Hoekstra O.S., Mottaghy F.M., Dietlein M., Guermazi A., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007, 25:571-578.
Casasnovas O. TEP intérimaire dans les lymphomes. Medecine Nucleaire 2014, 38:184-187.
Terasawa T., Lau J., Bardet S., Couturier O., Hotta T., Hutchings M., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009, 27:1906-1914.
Hustinx R., Jerusalem G., Deprijk B. Tomographie à émission de positons et lymphomes. Medecine Nucleaire 2008, 32:449-455.
Bodet-Milin C., Salaun P.Y., Crespin C., Vuillez J.P., Kraeber-Bodere F. La place de la TEP au FDG dans l'évaluation des lymphomes. Medecine Nucleaire 2009, 33:486-490.
Gallamini A., Hutchings M., Rigacci L., Specht L., Merli F., Hansen M., et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752.
Gallamini A., Rigacci L., Merli F., Nassi L., Bosi A., Capodanno I., et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91:475-481.
Cerci J.J., Pracchia L.F., Linardi C.C.G., Pitella F.A., Delbeke D., Izaki M., et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010, 51:1337-1343.
Zinzani P.-L., Rigacci L., Stefoni V., Broccoli A., Puccini B., Castagnoli A., et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 2012, 39:4-12.
Hutchings M., Loft A., Hansen M., Pedersen L.M., Buhl T., Jurlander J., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59.
Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., Timothy A.R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005, 16:1160-1168.
Zinzani P.-L., Gandolfi L., Broccoli A., Argnani L., Fanti S., Pellegrini C., et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 2011, 117:1010-1018.
Yang D.-H., Min J.-J., Song H.-C., Jeong Y.Y., Chung W.-K., Bae S.-Y., et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011, 47:1312-1318.
Cashen A.F., Dehdashti F., Luo J., Homb A., Siegel B.A., Bartlett N.L. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 2011, 52:386-392.
Pregno P., Chiappella A., Bellò M., Botto B., Ferrero S., Franceschetti S., et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012, 119:2066-2073.
Safar V., Dupuis J., Itti E., Jardin F., Fruchart C., Bardet S., et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012, 30:184-190.
Yoo C., Lee D.H., Kim J.E., Jo J., Yoon D.H., Sohn B.S., et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011, 90:797-802.
Querellou S., Valette F., Bodet-Milin C., Oudoux A., Carlier T., Harousseau J.-L., et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006, 85:759-767.
Hutchings M., Barrington S.F. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009, 50(Suppl. 1):21S-30S.
Barrington S.F., Mackewn J.E., Schleyer P., Marsden P.K., Mikhaeel N.G., Qian W., et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol 2011, 22:739-745.
Scheuermann J.S., Saffer J.R., Karp J.S., Levering A.M., Siegel B.A. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med 2009, 50:1187-1193.
Barrington S.F., Mikhaeel N.G., Kostakoglu L., Meignan M., Hutchings M., Müeller S.P., et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014, 32:3048-3058.
Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998, 339:1506-1514.
Tychyj-Pinel C., Ricard F., Giammarile F. TEP/TDM au FDG et bilan initial des lymphomes: du diagnostic au pronostic. Medecine Nucleaire 2011, 35:8-20.
Setoain X., López-Guillermo A., Rodríguez S., Navales I. TEP/TDM dans le diagnostic et la stadification des lymphomes. Medecine Nucleaire 2011, 35:4-7.
Weiler-Sagie M., Bushelev O., Epelbaum R., Dann E.J., Haim N., Avivi I., et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010, 51:25-30.
Tsukamoto N., Kojima M., Hasegawa M., Oriuchi N., Matsushima T., Yokohama A., et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with67gallium scintigraphy in the evaluation of lymphoma. Cancer 2007, 110:652-659.
Schoder H., Noy A., Gönen M., Weng L., Green D., Erdi Y.E., et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:4643-4651.
Watanabe R., Tomita N., Takeuchi K., Sakata S., Tateishi U., Tanaka M., et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 2010, 51:279-283.
Bodet-Milin C., Touzeau C., Leux C., Sahin M., Moreau A., Maisonneuve H., et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 2010, 37:1633-1642.
Moulin-Romsee G., Hindié E., Cuenca X., Brice P., Decaudin D., Bénamor M., et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010, 37:1095-1105.
Hutchings M. The role of bone marrow biopsy in Hodgkin lymphoma staging: "to be, or not to be, that is the question"?. Leuk Lymphoma 2012, 53:523-524.
Adams M.C.M., Turkington T.G.T., Wilson J.M.J., Wong T.Z.T. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010, 195:310-320.
El-Galaly T.C., D'Amore F., Mylam K.J., de Nully Brown P., Bøgsted M., Bukh A., et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012, 30:4508-4514.
Berthet L., Cochet A., Kanoun S., Berriolo-Riedinger A., Humbert O., Toubeau M., et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 2013, 54:1244-1250.
Pelosi E., Penna D., Douroukas A., Bellò M., Amati A., Arena V., et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 2011, 55:469-475.
Ngeow J.Y.Y., Quek R.H.H., Ng D.C.E., Hee S.W., Tao M., Lim L.C., et al. Uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 2009, 20:1543-1547.
Mittal B.R., Manohar K., Malhotra P., Das R., Kashyap R., Bhattacharya A., et al. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?. Leuk Lymphoma 2011, 52:2111-2116.
Chen Y.-K., Yeh C.-L., Tsui C.-C., Liang J.-A., Chen J.-H., Kao C.-H. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med 2011, 36:553-559.
Carr R., Barrington S.F., Madan B., O'Doherty M.J., Saunders C.A., van der Walt J., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998, 91:3340-3346.
Khan A.B., Barrington S.F., Mikhaeel N.G., Hunt A.A., Cameron L., Morris T., et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013, 122:61-67.
Paone G., Itti E., Haïoun C., Gaulard P., Dupuis J., Lin C., et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging 2009, 36:745-750.
Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014, 32:3059-3068.
Mikhaeel N.G. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. Leuk Lymphoma 2009, 50:1931-1936.
Meignan M., Gallamini A., Meignan M., Gallamini A., Haïoun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009, 50:1257-1260.
Barrington S.F., Qian W., Somer E.J., Franceschetto A., Bagni B., Brun E., et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010, 37:1824-1833.
Furth C., Amthauer H., Hautzel H., Steffen I.G., Ruf J., Schiefer J., et al. Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 2011, 22:1198-1203.
Biggi A., Gallamini A., Chauvie S., Hutchings M., Kostakoglu L., Gregianin M., et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013, 54:683-690.
Itti E., Meignan M., Berriolo-Riedinger A., Biggi A., Cashen A.F., Vera P., et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and δSUVmax. Eur J Nucl Med Mol Imaging 2013, 40:1312-1320.
Trotman J. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol 2014, e17-e27.
Martelli M., Ceriani L., Zucca E., Zinzani P.-L., Ferreri A.J.M., Vitolo U., et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014, 32:1769-1775.
Spaepen K., Stroobants S., Dupont P., Vandenberghe P., Maertens J., Bormans G., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003, 102:53-59.
Haïoun C., Itti E., Rahmouni A., Brice P., Rain J.-D., Belhadj K., et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005, 106:1376-1381.
Yang M., Gao H., Yan Y., Sun X., Chen K., Quan Q., et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 2011, 38:1237-1247.
Haioun C., Rahmouni A., Reyes F., Meignan M. Lymphome agressif à grandes cellules : appréciation précoce de l'efficacité thérapeutique par la TEP au [18F]-FDG. Med Nucl Imag Fonct Metab 2004, 28(7):327-333.
Mikhaeel N.G., Hutchings M., Fields P.A., O'Doherty M.J., Timothy A.R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005, 16:1514-1523.
Radford J., Illidge T., Counsell N., Hancock B., Pettengell R., Johnson P., et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015, 372:1598-1607.
Kostakoglu L., Goldsmith S.J., Leonard J.P., Christos P., Furman R.R., Atasever T., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006, 107:2678-2687.
Spaepen K., Stroobants S., Dupont P., Vandenberghe P., Thomas J., de Groot T., et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13:1356-1363.
Moskowitz C.H., Schoder H., Teruya-Feldstein J., Sima C., Iasonos A., Portlock C.S., et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010, 28:1896-1903.
Mamot C., Klingbiel D., Hitz F., Renner C., Pabst T., Driessen C., et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015, 33:2523-2529.
Barrington S.F., O'Doherty M.J. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003, 30(Suppl. 1):S117-S127.
Cook G.J.R., Wegner E.A., Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004, 34:122-133.
Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004, 45:1431-1434.
Gordien P., Morliere C., Bordenave L., Hindie E. Variation de la captation hépatique de 18-FDG dans l'évaluation intermédiaire des lymphomes B diffus à grandes cellules en TEP/TDM. Medecine Nucleaire 2014, 38:83-90.
Vriens D., Visser E.P., de Geus-Oei L.-F., Oyen W.J.G. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 2010, 37:1408-1425.
Geworski L., Knoop B.O., de Wit M., Ivancević V., Bares R., Munz D.L. Multicenter comparison of calibration and cross calibration of PET scanners. J Nucl Med 2002, 43:635-639.
Bouchet F., Geworski L., Knoop B.O., Ferrer L., Barriolo-Riedinger A., Millardet C., et al. Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT. PLoS ONE 2013, 8:e58152.
Boellaard R., O'Doherty M.J., Weber W.A., Mottaghy F.M., Lonsdale M.N., Stroobants S.G., et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37:181-200.
Boellaard R., Oyen W.J.G., Hoekstra C.J., Hoekstra O.S., Visser E.P., Willemsen A.T., et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008, 35:2320-2333.
Quak E., Hovhannisyan N., Lasnon C., Fruchart C., Vilque J.-P., Musafiri D., et al. The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria. Haematologica 2014, 99:e84-e85.
Krak N.C., Boellaard R., Hoekstra O.S., Twisk J.W.R., Hoekstra C.J., Lammertsma A.A. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005, 32:294-301.
Boellaard R.R., Krak N.C.N., Hoekstra O.S.O., Lammertsma A.A.A. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004, 45:1519-1527.
Lin C., Itti E., Haïoun C., Petegnief Y., Luciani A., Dupuis J., et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007, 48:1626-1632.
Itti E., Lin C., Dupuis J., Paone G., Capacchione D., Rahmouni A., et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009, 50:527-533.
Casasnovas R.-O., Meignan M., Berriolo-Riedinger A., Bardet S., Julian A., Thieblemont C., et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011, 118:37-43.
Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl. 1):122S-150S.
Hallett W.A., Marsden P.K., Cronin B.F., O'Doherty M.J. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 2001, 28:919-922.
de Langen A.J., Vincent A., Velasquez L.M., van Tinteren H., Boellaard R., Shankar L.K., et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med 2012, 53:701-708.
Sasanelli M., Meignan M., Haïoun C., Berriolo-Riedinger A., Casasnovas R.-O., Biggi A., et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 2014, 41:2017-2022.
Kanoun S., Rossi C., Berriolo-Riedinger A., Dygai-Cochet I., Cochet A., Humbert O., et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2014, 41:1735-1743.
Ceriani L., Martelli M., Zinzani P.-L., Ferreri A.J.M., Botto B., Stelitano C., et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 2015, 126:950-956.
Meignan M., Gallamini A., Itti E., Barrington S., Haïoun C., Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012, 53:1876-1881.
